GastroHep最新文献

{"title":"Gastric precancerous conditions in patients with chronic dyspepsia","authors":"T. Win, K. Aye, T. Aye","doi":"10.1002/ygh2.483","DOIUrl":"https://doi.org/10.1002/ygh2.483","url":null,"abstract":"Gastric cancer (GC) is one of the most lethal malignancies worldwide, though a decrease in incidence. Helicobacter pylori is positively associated with gastric precancerous conditions. Detection of these conditions, namely atrophic gastritis (AG) and intestinal metaplasia (IM), and their association with H pylori infection is important for further detection and reduction of overall cancer incidence.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"21 1","pages":"366 - 371"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73428912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose dual therapy and CYP2C19 polymorphism in Helicobacter pylori eradication","authors":"Tin Ma Ma Win,&nbsp;Min Htun,&nbsp;Win Phyu Phyu Myint,&nbsp;Moe Myint Aung,&nbsp;Nwe Ni","doi":"10.1002/ygh2.484","DOIUrl":"https://doi.org/10.1002/ygh2.484","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> infect about 50% of the world's population. The efficacy of treatment using standard regimens has declined in recent years, mainly due to widespread development of antibiotic resistance. Use of enhanced acid suppression and antibiotics with lower risk to resistance, will shape the future of treatment for <i>H pylori</i>. High-dose dual therapy (HDDT) can overcome the effect of CYP2C19 polymorphism thus enhancing acid suppression and may become an option in <i>H pylori</i> eradication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To describe the eradication rate and side effects of HDDT in different metaboliser status relating to CYP2C19 polymorphism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This is a hospital-based cross-sectional analytic study. A total of 63 <i>H pylori</i>-infected patients diagnosed using rapid urease test and histology were given HDDT for 14 days. Urea breath test was done 4 weeks after cessation of HDDT. CYP2C19 polymorphism was tested using the PCR-RFLP method. The eradication rates of HDDT were compared according to CYP2C19 polymorphism status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Over all eradication rate of HDDT was 69.8% (95% CI 57%-80.8%). According to CYP2C19 polymorphism, 26.9% were homozygous extensive metabolisers (HomEM), 66.7% were heterozygous extensive metabolisers (HetEM) and 6.4% were poor metabolisers (PM). Eradication rate of HDDT was 82.4%, 69% and 25% in HomEM, HetEM and PM respectively. Only 16% of patients reported minor side effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Eradication rate of HDDT was fairly satisfactory for both homozygous and heterozygous extensive metaboliser states. This finding suggested that HDDT can overcome the effect of CYP2C19 polymorphism.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 6","pages":"379-383"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.484","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71987423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric precancerous conditions in patients with chronic dyspepsia","authors":"Thet-Mar Win,&nbsp;Khin-San Aye,&nbsp;Than-Than Aye","doi":"10.1002/ygh2.483","DOIUrl":"https://doi.org/10.1002/ygh2.483","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Gastric cancer (GC) is one of the most lethal malignancies worldwide, though a decrease in incidence. <i>Helicobacter pylori</i> is positively associated with gastric precancerous conditions. Detection of these conditions, namely atrophic gastritis (AG) and intestinal metaplasia (IM), and their association with <i>H pylori</i> infection is important for further detection and reduction of overall cancer incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To detect the prevalence of <i>H pylori</i> infection and gastric precancerous conditions in patients with chronic dyspepsia by High Definition White Light Endoscopy (HD-WLE) and Narrow Band Imaging with Magnifying Endoscopy (NBI-ME).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a hospital-based descriptive study including chronic dyspeptic patients aged over 50 years. <i>H pylori</i> infection was diagnosed by a rapid urease test. AG and IM were detected by endoscopy (HD-WLE and NBI-ME) and confirmed by histology. Detection rates of each method were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Totally 143 patients (55 males/88 females) with a mean age of 64.57 ± 9.957 years were included. <i>H pylori</i> infection rate was 53.84% (n = 77). Twenty-two patients with AG (44.9% of patients with atrophy) and 37.84% (14/37) of patients with IM have <i>H pylori</i> infection. There was a statistically significant difference in detection rates between HD-WLE and NBI-ME for IM (<i>P</i>=0.001) but not for AG (<i>P</i>=0.250).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>H pylori</i> infection is still high in Myanmar. There were significant associations between <i>H pylori</i> and gastric precancerous lesions. Detection of atrophic gastritis and intestinal metaplasia by routine usage of NBI-ME along with test and treat <i>H pylori</i> infection are the strategies to reduce the incidence of gastric cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 6","pages":"366-371"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.483","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71987014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bismuth-based quadruple therapy vs concomitant therapy for Helicobacter pylori eradication—a real-world experience","authors":"David Mathew Thomas,&nbsp;Krishnadas Devadas","doi":"10.1002/ygh2.486","DOIUrl":"https://doi.org/10.1002/ygh2.486","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Both bismuth-based quadruple therapy (BQT) and concomitant therapy (CCT) are first-line regimens for <i>Helicobacter pylori</i> eradication. We compared the efficacy and adverse effects of both regimens in day-to-day clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adult patients with biopsy-proven <i>H. pylori</i> infection were included. Drug therapy was based on patient and physician preference. Both BQT and CCT regimens were given for 14 days. Efficacy was assessed using a stool antigen for <i>H. pylori</i> 4 weeks after treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and twenty-nine consecutive patients were analysed, and the demographic characteristics of the two groups were similar. Treatment compliance was comparable in both regimens (<i>P</i> = 0.074), and 12/81 (14.8%) and 3/48 (12.5%) defaulted in BQT and CCT groups, respectively. 64.2% and 48% of patients reported some adverse effect in BQT and CCT groups (<i>P</i> = 0.10). Predominant adverse effects reported were nausea (41.9% vs 25%), black stools (29.6% vs 2%), vomiting (24.7% vs 6.25%) and loose stools (9.8% vs 20.8%) in BQT and CCT groups. Treatment efficacy of BQT and CCT regimen by intention-to-treat analysis was 87.7% (n = 71/81) and 79.2% (n = 38/48) (<i>P</i> = 0.321) and by per-protocol was 89.9% (n = 62/69) and 82.2% (n = 37/45) (<i>P</i> = 0.37).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Treatment efficacy with BQT is equivalent to CCT for <i>H. pylori</i> eradication. Both regimens have similar compliance rates, adverse events and affordability. With rising antibiotic resistance, BQT should be considered a better first-line option for <i>H. pylori</i> eradication.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 6","pages":"388-393"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.486","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71987422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus-infected persons treated with direct-acting antivirals: Public health impact amongst Swedish cohort in the Covid-19 pandemic era","authors":"Saumya Pandey","doi":"10.1002/ygh2.470","DOIUrl":"https://doi.org/10.1002/ygh2.470","url":null,"abstract":"To the Editor: The study by Lybeck et al1 focusing on riskassessment of extrahepatic cancer (EHC) in a nationwide Swedish cohort of hepatitis C virus (HCV) infected persons treated with direct acting antivirals (DAAs) provides critical insights in the patientfriendly, costeffective, timelinebased clinical management of HCVmediated EHC (eg nonHodgkin lymphoma/intrahepaticcholangiocarcinoma) for eventual design/development of novel immunomodulatory drugs and predictive/prognostic biomarkers in “atrisk” susceptible populations of varying genetic landscapes. Inclusion/exclusioncriteria were welldefined with a biasfree interpretation of complex statistical datasets; large sample size (N = 19 685 HCVpositive cases), a major study strength, added adequate statistical power (≥80%) reducing the possibility of potential selection bias in risk assessment amongst subgroups of HCVinfected persons: 4013 DAAtreated/3071 interferon (IFN)treated/12 601 untreated, with maximal 3 years’ clinical followup time. EHC risk was compared between treatment groups using Cox regression analyses, with adjustment for age/Charlson Comorbidity Index (CCI); matched case– control studyapproach wherein HCVinfected groups were stringently compared with matched cohorts without HCV from general Swedish population, reduced possibility of populationadmixture. Healthy/diseasefree, age/ethnicitymatched controls from random population significantly adds to statisticalpower of case– control association studies in “gastrohepatic diseaseweb”pathophysiology research2,3; Pandey has elegantly emphasized the significance of age/ethnicitymatched diseasefree controls from the general random population in multicentric epidemiology/ pharmacogenetics/genomics studies for demystifying the cellular/ molecular/genetic basis of inflammatory gastrohepatic ailments in susceptible cohorts.4 Overall, the findings of this study on HCVmediated EHC management in Swedish cohort(s) convincingly demonstrated that the HCVpositivity trend amongst 341 EHCs was appreciable: 84/43/214 EHC in DAA/IFN/untreatedgroup respectively; EHCrisk in DAAtreated compared with IFNtreated was doubled, but after adjustment for age/CCI, hazards ratio (HR) was 1.07 (95% CI 0.741.56). Cox regression analysis with controls revealed that EHCHR in DAAgroup = 1.45 (CI 1.131.86), with difference remaining statistically significant after adjusting for CCI. These findings may be successfully replicated in future multicentric large sample sizebased case– control prospective studies adhering to core tenets of good practice ethical research with longterm patient satisfaction trends. Interestingly, data from the HCVinfected EHCcohort and matched comparisoncohort were linked to national registers with prospectively collected data (National Board of Health and Welfare: PrescriptionRegister (PrR)/PatientRegister (PR)/CancerRegister (CR)/CauseofDeathRegister (DR)), adding authenticity to the selectioncriteria of eligible studysubjects of Swedish ethnic","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 4","pages":"270-271"},"PeriodicalIF":0.0,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.470","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71981754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levofloxacin‐based Helicobacter pylori eradication in chronic dyspepsia","authors":"W. Aung, T. Aye, K. Aye, A. Kyaw","doi":"10.1002/ygh2.478","DOIUrl":"https://doi.org/10.1002/ygh2.478","url":null,"abstract":"Helicobacter pylori infection in dyspepsia is an important clinical problem with increasing antibiotic resistance.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"36 1","pages":"394 - 400"},"PeriodicalIF":0.0,"publicationDate":"2021-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81759898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of serum pepsinogens for atrophic gastritis in Myanmar","authors":"M. Tun, K. Aye, T. Aye","doi":"10.1002/ygh2.490","DOIUrl":"https://doi.org/10.1002/ygh2.490","url":null,"abstract":"Chronic atrophic gastritis (CAG) is a precancerous lesion of gastric cancer. This study investigated the diagnostic accuracy of serum pepsinogens in Myanmar to diagnose CAG as non‐invasive makers.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"437 1","pages":"352 - 358"},"PeriodicalIF":0.0,"publicationDate":"2021-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77036871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of levofloxacin‐based sequential regimen to eradicate Helicobacter pylori infection","authors":"Muhammad Mansoor ul Haq, M. Furqan, A. Zia, A. Khalil, H. Kalwar","doi":"10.1002/ygh2.482","DOIUrl":"https://doi.org/10.1002/ygh2.482","url":null,"abstract":"Infection with Helicobacter pylori is globally prevalent. It is a chronic infection, standard treatment of which includes two antibiotics, amoxicillin and clarithromycin, plus a proton pump inhibitor used for 1 or 2 weeks. However, owing to increased resistance in our country, definitive eradication of H pylori is difficult. We conducted this study to evaluate the efficacy of a regimen using levofloxacin for successful eradication of H pylori infection.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"4 1","pages":"384 - 387"},"PeriodicalIF":0.0,"publicationDate":"2021-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84742860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of levofloxacin-based sequential regimen to eradicate Helicobacter pylori infection","authors":"Muhammad Mansoor ul Haq,&nbsp;Muhammad Furqan,&nbsp;Ayesha Zia,&nbsp;Ayesha Khalil,&nbsp;Hamid Ali Kalwar","doi":"10.1002/ygh2.482","DOIUrl":"https://doi.org/10.1002/ygh2.482","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Infection with <i>Helicobacter pylori</i> is globally prevalent. It is a chronic infection, standard treatment of which includes two antibiotics, amoxicillin and clarithromycin, plus a proton pump inhibitor used for 1 or 2 weeks. However, owing to increased resistance in our country, definitive eradication of <i>H pylori</i> is difficult. We conducted this study to evaluate the efficacy of a regimen using levofloxacin for successful eradication of <i>H pylori</i> infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Subject and methods</h3>\u0000 \u0000 <p>This is a prospective study conducted at a tertiary care hospital. After informed written consent, all patients with proven <i>H pylori</i> infection (either by biopsy or by stool antigen test) were included in this study on the basis of other inclusion and exclusion criteria. Patients were given levofloxacin-based sequential therapy and stool for <i>H pylori</i> antigen was performed as per protocol to assess the eradication rate (ie, efficacy of levofloxacin-based regimen). Patients were required to fill a Performa for assessment of symptoms. Chi-square test was used for analysis. <i>P</i> &lt; 0.05 was considered as significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 149 patients with active <i>H pylori</i> infection were included. Out of 149 cases, 80 (53.7%) were male and 69 (46.3%) female. <i>H pylori</i> eradication was successfully achieved in 128 (85.9%) patients, 13 (8.7%) patients remained positive after eradication therapy and 8 (5.4%) patients lost follow up. No serious adverse event was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Levofloxacin-based sequential therapy was highly effective (85.9%) against chronic <i>H pylori</i> infection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 6","pages":"384-387"},"PeriodicalIF":0.0,"publicationDate":"2021-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71982390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal endoscopic full‐thickness resection: Initial experience from a tertiary centre in Singapore","authors":"C. K. Tan, J. W. Li, Lai Mun Wang, A. Kwek, T. Ang","doi":"10.1002/ygh2.480","DOIUrl":"https://doi.org/10.1002/ygh2.480","url":null,"abstract":"Colorectal endoscopic full‐thickness resection using the full‐thickness resection device is an emerging endoscopic therapy for non‐lifting adenomas and subepithelial lesions. We aim to describe our initial experience and examine the outcomes of colorectal endoscopic full‐thickness resection in our centre.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"21 1","pages":"298 - 306"},"PeriodicalIF":0.0,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80522461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}